Epidemiological studies of the side effects associated with Actos have been conducted or are on going in the U.S. and Europe.
Takeda Pharmaceutical Co., the maker of Actos® (pioglitazone), began an extensive ten-year in 2002, monitoring more than 193,000 patients. In September of 2010, the FDA announced a safety review of the preliminary findings in the Takeda study. The FDA’s subsequent analysis revealed a 40 percent increase in risk of bladder cancer in patients taking the drug longer than a year.
Used to treat type 2 diabetes, Actos® is designed to control blood sugar. The drug is sold alone or in combination with Actoplus Met, Actoplus Met XR and Duetact. In 2010, more than 2 million patients in the U. S. were taking these drugs, according to the FDA.
Below are links related to Actos® safety announcements and news stories.
U.S. Food and Drug Administration
FDA Drug Safety Communication
New England Journal of Medicine – Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
The law firm of Rudolph F.X. Migliore, P.C. is investigating potential Actos® lawsuits, with co-counsel for clients nationwide. If you or a loved one has taken Actos® and has developed bladder cancer, take advantage of our firm’s free case evaluation. Call our law firm today at (631) 543-3663 or use our contact form.
Find out if you are entitled to compensation for the harm you suffered. We take Actos®cases on a contingency basis. There is no fee unless we recover damages on your behalf.